- Home
- TXN vs AZN Comparison
TXN vs AZN Comparison
Compare TXN & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXN | AZN |
|---|---|---|
| Founded | 1930 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.9B | 285.7B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | TXN | AZN |
|---|---|---|
| Price | $194.53 | $191.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 1 |
| Target Price | ★ $217.13 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 1.7M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.93% | 1.67% |
| EPS Growth | ★ 4.81 | N/A |
| EPS | ★ 5.45 | N/A |
| Revenue | ★ $17,682,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.41 | $6.21 |
| P/E Ratio | $35.62 | ★ $31.91 |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $139.95 | $61.24 |
| 52 Week High | $231.32 | $212.71 |
Technical Indicators
Market Signals| Indicator | TXN | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 38.07 | 57.42 |
| Support Level | $174.78 | $89.28 |
| Resistance Level | $203.35 | $211.32 |
| Average True Range (ATR) | 4.61 | 3.16 |
| MACD | -2.30 | -4.83 |
| Stochastic Oscillator | 16.55 | 13.41 |
Price Performance
Historical ComparisonAbout TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.